↓ Skip to main content

Pain Control

Overview of attention for book
Attention for Chapter 7: The role of the endocannabinoid system in pain.
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#30 of 655)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
3 news outlets
twitter
5 X users
facebook
7 Facebook pages
wikipedia
1 Wikipedia page

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
204 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
The role of the endocannabinoid system in pain.
Chapter number 7
Book title
Pain Control
Published in
Handbook of experimental pharmacology, January 2015
DOI 10.1007/978-3-662-46450-2_7
Pubmed ID
Book ISBNs
978-3-66-246449-6, 978-3-66-246450-2
Authors

Woodhams, Stephen G, Sagar, Devi Rani, Burston, James J, Chapman, Victoria, Stephen G. Woodhams, Devi Rani Sagar, James J. Burston, Victoria Chapman, Woodhams, Stephen G., Burston, James J.

Abstract

Preparations of the Cannabis sativa plant have been used to analgesic effect for millenia, but only in recent decades has the endogenous system responsible for these effects been described. The endocannabinoid (EC) system is now known to be one of the key endogenous systems regulating pain sensation, with modulatory actions at all stages of pain processing pathways. The EC system is composed of two main cannabinoid receptors (CB1 and CB2) and two main classes of endogenous ligands or endocannabinoids (ECs). The receptors have distinct expression profiles, with CB1 receptors found at presynaptic sites throughout the peripheral and central nervous systems (PNS and CNS, respectively), whilst CB2 receptor is found principally (but not exclusively) on immune cells. The endocannabinoid ligands are lipid neurotransmitters belonging to either the N-acyl ethanolamine (NAEs) class, e.g. anandamide (AEA), or the monoacylglycerol class, e.g. 2-arachidonoyl glycerol (2-AG). Both classes are short-acting transmitter substances, being synthesised on demand and with signalling rapidly terminated by specific enzymes. ECs acting at CB1 negatively regulate neurotransmission throughout the nervous system, whilst those acting at CB2 regulate the activity of CNS immune cells. Signalling through both of these receptor subtypes has a role in normal nociceptive processing and also in the development resolution of acute pain states. In this chapter, we describe the general features of the EC system as related to pain and nociception and discuss the wealth of preclinical and clinical data involving targeting the EC system with focus on two areas of particular promise: modulation of 2-AG signalling via specific enzyme inhibitors and the role of spinal CB2 in chronic pain states.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 204 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Denmark 1 <1%
Brazil 1 <1%
Unknown 201 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 28 14%
Student > Ph. D. Student 23 11%
Student > Master 22 11%
Researcher 21 10%
Student > Doctoral Student 14 7%
Other 32 16%
Unknown 64 31%
Readers by discipline Count As %
Medicine and Dentistry 44 22%
Neuroscience 24 12%
Biochemistry, Genetics and Molecular Biology 16 8%
Pharmacology, Toxicology and Pharmaceutical Science 14 7%
Agricultural and Biological Sciences 10 5%
Other 26 13%
Unknown 70 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2023.
All research outputs
#1,004,984
of 23,730,866 outputs
Outputs from Handbook of experimental pharmacology
#30
of 655 outputs
Outputs of similar age
#14,067
of 356,824 outputs
Outputs of similar age from Handbook of experimental pharmacology
#6
of 66 outputs
Altmetric has tracked 23,730,866 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 655 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.0. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,824 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.